title: Microbiota in Functional Gastrointestinal Disorders in Infancy: Implications for Management.
abstract: The complex and diverse intestinal microbiome is recognized as important in promoting human health. An altered gut microflora, referred to as dysbiosis, is increasingly recognized as having an etiologic role in a variety of conditions, including functional gastrointestinal disorders: colic in infants and irritable bowel syndrome in older children. Probiotics are defined as live microorganisms that, if ingested in sufficient amounts, restore microbial homeostasis and have a benefit on health. Randomized controlled trials indicate that probiotics can be effective in a variety of intestinal conditions, including colic and irritable bowel syndrome. Probiotics may promote gut microbial diversity, but timing of the intervention appears crucial. Strain-specific effects on colonization resistance, epithelial barrier integrity, modulation of signal transduction, impacts on innate and adaptive immune responses, and effects on visceral hyperalgesia likely explain the observed variability in various probiotic strains. In the future, probiotics are likely to be chosen for use in a defined clinical setting based on underlying mechanism(s) of action. The precise component of the probiotic agent mediating observed effects is the subject of current research. Unresolved issues relate to optimal dosages, timing of ingestion, single versus combination formulations, maintenance of viability in storage, and the merits of employing probiotic-derived products.
authors.forename: Thomas R
authors.initials: TR
authors.lastname: Abrahamsson
authors.forename: Richard Y
authors.initials: RY
authors.lastname: Wu
authors.forename: Philip M
authors.initials: PM
authors.lastname: Sherman
mesh_terms: D000818:Animals; D001644:Bifidobacterium; D002648:Child; D003085:Colic / Q000382:microbiology / Q000628:therapy; D064806:Dysbiosis; D005243:Feces / Q000382:microbiology; D005767:Gastrointestinal Diseases / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology*; D000069196:Gastrointestinal Microbiome / Q000502:physiology*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D043183:Irritable Bowel Syndrome / Q000382:microbiology; D007778:Lactobacillus; D019936:Probiotics / Q000627:therapeutic use